Industry

Timing of PPV a biomarker for vision gains in DME

Healio Optometry1d ago1 min read

FORT LAUDERDALE, Fla. — In patients with diabetic macular edema, small gauge pars plana vitrectomy should be considered as a first-line treatment, according to a speaker at Retina World Congress.“The burden of injection today is almost impossible to follow,” Matias Iglicki, MD, said during a presentation. “We have to do something now before we face the consequences.”Iglicki and colleagues aimed to investigate the visual and anatomic outcomes of small gauge pars plana vitrectomy (PPV) through 24 months for patients with treatment-naïve DME. The multicenter study analyzed 120 eyes across 120

Read full article on Healio Optometry

AI Summary

Quick Take

New research presented at the Retina World Congress suggests that small gauge pars plana vitrectomy (PPV) should be considered as a first-line treatment for treatment-naïve diabetic macular edema (DME). Dr. Matias Iglicki reported that in a multicenter study of 120 eyes, the timing of the surgical intervention served as a key biomarker for visual gains over a 24-month period.

Why It Matters

The current standard of care for DME relies heavily on anti-VEGF injections, but the 'injection burden'—the frequency of visits and shots required—is increasingly unsustainable for many patients and providers. When patients miss appointments in the real world, they lose the visual gains seen in clinical trials. Shifting PPV from a 'last resort' to an early-stage option could provide more stable anatomical outcomes and relieve the logistical pressure on the healthcare system.

Key Findings

Small gauge pars plana vitrectomy (PPV) demonstrated significant visual and anatomic benefits when used as a primary treatment for treatment-naïve DME.
The timing of the PPV procedure is a critical biomarker, suggesting that earlier intervention leads to better long-term visual outcomes.
The study followed 120 eyes over a 24-month duration, providing evidence for the durability of surgical intervention compared to the repetitive nature of pharmacotherapy.
Researchers emphasized that the current burden of frequent injections is nearly impossible for many patients to follow, necessitating a shift in treatment paradigms.

Study Snapshot

Design

Multicenter study

Population

Patients with treatment-naïve diabetic macular edema

Sample Size

120 eyes (120 patients)

Practice Implications

Retina specialists may need to re-evaluate the DME treatment algorithm, moving surgical consultation earlier for patients who are likely to struggle with the compliance requirements of chronic injections. Monitoring the timing of intervention is essential, as delaying surgery until after multiple failed injections may limit the ultimate visual recovery potential.

Who's Affected

Retina SpecialistsOphthalmologistsPractice Owners

What's Next

As the clinical community processes these findings, further peer-reviewed data from this multicenter cohort will be vital to determine if PPV can officially challenge anti-VEGF as a primary standard of care. Watch for updated clinical guidelines regarding the management of treatment-naïve DME patients.

Evidence StrengthModerate

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.